Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

Author:

Rodrigo M. J.12345ORCID,Cardiel M. J.67849ORCID,Fraile J. M.101112134ORCID,Mendez-Martinez S.12345ORCID,Martinez-Rincon T.12345,Subias M.12345ORCID,Polo V.12345,Ruberte J.144151617,Ramirez T.67849,Vispe E.181011123,Luna C.678418,Mayoral J. A.101112134,Garcia-Martin E.12345

Affiliation:

1. Department of Ophthalmology

2. Miguel Servet University Hospital

3. Zaragoza

4. Spain

5. Aragon Institute for Health Research (IIS Aragon)

6. Miguel Servet Ophthalmology Research Group (GIMSO)

7. Aragon Health Research Institute (IIS Aragon)

8. University of Zaragoza

9. Department of Pathology

10. Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH)

11. Faculty of Sciences

12. University of Zaragoza-CSIC

13. E-50009 Zaragoza

14. RETICS: Thematic Networks for Co-operative Research in Health for Ocular Diseases

15. Centre for Animal Biotechnology and Gene Therapy (CBATEG)

16. Universitat Autònoma de Barcelona

17. Bellaterra

18. Chromatography and Spectroscopy Laboratory

Abstract

Brimonidine-LAPONITE® formulation is a potential intravitreal formulation for glaucoma treatment. It exhibits an early ocular hypotensive effect and functional and structural neuroretinal protection over 24 weeks of follow-up, after single injection. 

Funder

Ministerio de Ciencia e Innovación

Instituto de Salud Carlos III

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3